Key facts
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Cytek Biosciences Inc Common Stock.
- Disclosed ownership: 7.5%.
- Date of event: 31 Mar 2025.
VANGUARD GROUP INC - 31 Mar 2025 SCHEDULE 13G/A Report for Cytek Biosciences Inc Common Stock
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Cytek Biosciences Inc Common Stock
- Shares outstanding
- 128,122,610 shares
- Disclosed Ownership
- 9,622,008 shares
- Ownership
- 7.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Apr 2025, 10:57:47 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Key filing fact
VANGUARD GROUP INC disclosed 7.5% ownership in Cytek Biosciences Inc Common Stock on 31 Mar 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Apr 2025, 10:57.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 7.5% | 9,622,008 | 0 | 76,501 | Ashley Grim | Head of Global Fund Administration |
CIK / CUSIP context first